Swiss National Bank boosted its position in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 1.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 34,707 shares of the medical research company’s stock after purchasing an additional 500 shares during the period. Swiss National Bank owned approximately 0.12% of Bio-Rad Laboratories worth $7,855,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Eagle Asset Management Inc. lifted its stake in Bio-Rad Laboratories by 1.8% in the second quarter. Eagle Asset Management Inc. now owns 30,782 shares of the medical research company’s stock worth $6,966,000 after purchasing an additional 540 shares during the last quarter. Pacad Investment Ltd. bought a new stake in Bio-Rad Laboratories in the second quarter worth about $113,000. Chicago Equity Partners LLC bought a new stake in Bio-Rad Laboratories in the second quarter worth about $1,064,000. Principal Financial Group Inc. lifted its stake in Bio-Rad Laboratories by 4.8% in the second quarter. Principal Financial Group Inc. now owns 89,043 shares of the medical research company’s stock worth $20,151,000 after purchasing an additional 4,084 shares during the last quarter. Finally, Capital Analysts LLC bought a new stake in Bio-Rad Laboratories in the second quarter worth about $170,000. 62.85% of the stock is owned by institutional investors and hedge funds.

In other Bio-Rad Laboratories news, EVP Michael Crowley sold 700 shares of the business’s stock in a transaction dated Friday, August 11th. The shares were sold at an average price of $215.91, for a total value of $151,137.00. Following the transaction, the executive vice president now directly owns 2,060 shares in the company, valued at approximately $444,774.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 28.29% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Swiss National Bank Has $7.86 Million Holdings in Bio-Rad Laboratories, Inc. (BIO)” was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://www.dailypolitical.com/2017/09/15/swiss-national-bank-has-7-86-million-holdings-in-bio-rad-laboratories-inc-bio.html.

Bio-Rad Laboratories, Inc. (NYSE:BIO) opened at 224.33 on Friday. The stock has a market capitalization of $6.65 billion, a price-to-earnings ratio of 443.34 and a beta of 0.93. The stock’s 50 day moving average is $221.37 and its 200-day moving average is $216.87. Bio-Rad Laboratories, Inc. has a 12 month low of $154.89 and a 12 month high of $242.79.

BIO has been the subject of several analyst reports. Zacks Investment Research downgraded shares of Bio-Rad Laboratories from a “hold” rating to a “sell” rating in a research note on Thursday, August 10th. BidaskClub raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research note on Thursday, June 22nd. Jefferies Group LLC reissued a “buy” rating and issued a $275.00 price objective on shares of Bio-Rad Laboratories in a research note on Friday, July 14th. Wells Fargo & Company initiated coverage on shares of Bio-Rad Laboratories in a research note on Thursday, July 13th. They issued an “outperform” rating and a $250.00 price objective for the company. Finally, Deutsche Bank AG raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating and decreased their price objective for the stock from $220.00 to $195.00 in a research note on Wednesday, June 28th. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $228.80.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO).

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.